Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 USD | -3.49% | -.--% | +3.75% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 55.48M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -23M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.55
x | P/E ratio 2025 * |
-2.41
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.86% |
1 day | -3.49% | ||
1 month | -0.60% | ||
3 months | +0.61% | ||
6 months | -73.82% | ||
Current year | +3.75% |
Managers | Title | Age | Since |
---|---|---|---|
Niall O'Donnell
FOU | Founder | 51 | - |
Gregory Flesher
CEO | Chief Executive Officer | 54 | 20-12-08 |
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Director/Board Member | 64 | 17-11-30 | |
Paul Hoelscher
BRD | Director/Board Member | 59 | 22-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.49% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.66 | -3.49% | 108,667 |
24-05-30 | 1.72 | +1.78% | 50,715 |
24-05-29 | 1.69 | -2.87% | 83,705 |
24-05-28 | 1.74 | +4.82% | 146,618 |
24-05-24 | 1.66 | -4.05% | 135,156 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.75% | 57.48M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- RPHM Stock